Ontology highlight
ABSTRACT: We used massively parallel sequencing technology to sequence the genomic DNA of tumor cells (leukemic bone marrow) and normal cells (skin biopsy) obtained from patients with Acute Myeloid Leukemia (AML). Patients had either de novo AML (AML with no prior diagnosis of a hematologic disease or exposure to chemotherapy), secondary AML (occurring after a prior diagnosis of myelodysplastic syndromes (MDS)), or therapy-related AML (occurring after exposure to prior chemotherapy). We identified somatic mutations in the tumor genomes, including single nucleotide variants, insertions, deletions, and structural variants.
PROVIDER: phs000159.v4.p2 | EGA |
REPOSITORIES: EGA
Graubert Timothy A TA Shen Dong D Ding Li L Okeyo-Owuor Theresa T Lunn Cara L CL Shao Jin J Krysiak Kilannin K Harris Christopher C CC Koboldt Daniel C DC Larson David E DE McLellan Michael D MD Dooling David J DJ Abbott Rachel M RM Fulton Robert S RS Schmidt Heather H Kalicki-Veizer Joelle J O'Laughlin Michelle M Grillot Marcus M Baty Jack J Heath Sharon S Frater John L JL Nasim Talat T Link Daniel C DC Tomasson Michael H MH Westervelt Peter P DiPersio John F JF Mardis Elaine R ER Ley Timothy J TJ Wilson Richard K RK Walter Matthew J MJ
Nature genetics 20111211 1
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy-resistant secondary acute myeloid leukemia (sAML). We used whole-genome sequencing to perform an unbiased comprehensive screen to discover the somatic mutations in a sample from an individual with sAML and genotyped the loci containing these mutations in the matched MDS sample. Here we show that a missense mutation affecting the serine at codon 34 (Ser34) in U2AF1 was recurrently present in ...[more]